Adi Hoess, Affimed CEO
AACR22: Affimed's NK cell therapy produces more patient responses — and more durability questions
NEW ORLEANS — One year after surprising the AACR crowd with solid initial NK cell data, Affimed is back with another cut Sunday.
And while …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
